Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

Authors

null

Yasuyuki Kawamoto

Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

Yasuyuki Kawamoto , Satoshi Yuki , Kentaro Sawada , Michio Nakamura , Osamu Muto , Susumu Sogabe , Yoshiaki Shindo , Atsushi Ishiguro , Atsushi Sato , Yasushi Tsuji , Masayoshi Dazai , Hiroyuki Okuda , Takahide Sasaki , Kazuaki Harada , Shintaro Nakano , Hiroshi Nakatsumi , Mari Sekiguchi , Yuh Sakata , Naoya Sakamoto , Yoshito Komatsu

Organizations

Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan, Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan, Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan, Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan, Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan, Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, Department of Medical Oncology, Tonan Hospital, Sapporo, Japan, Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan, Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan, Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Data Center, Hokkaido Gastrointestinal Cancer Study Group, Sapporo, Japan, CEO, Misawa City Hospital, Misawa, Japan

Research Funding

Pharmaceutical/Biotech Company
Eli Lilly Japan K.K

Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared with PTX alone for advanced gastric cancer (AGC) in second-line treatment. WJOG 4007 trial demonstrated equivalent efficacy between irinotecan (IRI) and PTX. We conducted this trial to examine the efficacy and safety of RAM plus IRI combination therapy in the second-line treatment for AGC. Methods: This non-randomized, single arm, phase 2 trial was carried out at 22 institutes in Japan. AGC patients with refractory or intolerance to primary chemotherapy were eligible. RAM 8 mg/kg and IRI 150 mg/m2 combination therapy administered every two weeks were continued until progression or emergence of adverse events requiring discontinuation. The primary endpoint was progression-free survival (PFS) rate at six-month, the target was set as 16% with an expected threshold of 39%. A total of 35 cases are planned for registration. The secondary endpoints were OS, PFS, response rate (RR) and safety. This trial was registered with Japan Registry of Clinical Trials, number jRCTs011180029. Results: Between Jan 2018 and Sept 2019, 35 patients were enrolled. Median age was 70 (range, 47-80); female/male were 10/25; ECOG PS 0/1, 22/13. PFS rate at six months was 26.5% (95%C.I., 13.2-41.8%, p = 0.1353). Median PFS and OS were 4.2 (95%C.I., 2.5-5.4 months) and 9.6 months (95%C.I., 6.5-16.6 months), respectively. RR was 26% and disease control rate was 85%. Grade 3 or higher adverse events that occurred in more than 5% of patients were neutropenia (51%), leucopenia (43%), anemia (20%), anorexia (14%), febrile neutropenia (11%), diarrhea (9%), hypertension (9%), proteinuria (9%), hypokalemia (9%), hypoalbuminemia (9%), thrombocytopenia (6%), and hyponatremia (6%). No death and new safety signals with a causal relation to study treatment were observed. Conclusions: Although the primary endpoint was not achieved statistically, the results are clinically encouraging, especially take into account that more elderly patients enrolled in this trial. The combination of RAM plus IRI has anti-cancer activity and manageable safety profile in second-line treatment for patients with AGC. Clinical trial information: jRCTs011180029.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

jRCTs011180029

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 217)

DOI

10.1200/JCO.2021.39.3_suppl.217

Abstract #

217

Poster Bd #

Online Only

Abstract Disclosures